Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. The company's lead product candidate is reSET for treating substance use disorder. Its product pipeline includes reSET-O for the treatment of opioid use disorder (OUD) in conjunction with opioid replacement therapy; Somryst against chronic insomnia; PEAR-004 targeting schizophrenia; and PEAR-006 for treating multiple sclerosis. The company's PDT platform is developing therapies targeting Alzheimer's disease, autoimmune disorders, depression, gastrointestinal disorders, migraine, and pain. Pear Therapeutics works in collaboration with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc, Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Pear Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Pear Therapeutics Inc Company Overview
- Pear Therapeutics Inc Company Snapshot
- Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pear Therapeutics Inc - Pipeline Analysis Overview
- Pear Therapeutics Inc - Key Facts
- Pear Therapeutics Inc - Major Products and Services
- Pear Therapeutics Inc Pipeline Products by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc Pipeline Products Overview
- Alcohol Use Disorder DTx
- Alcohol Use Disorder DTx Product Overview
- Alzheimer’s Disease DTx
- Alzheimer’s Disease DTx Product Overview
- Autism Spectrum Disorder DTx
- Autism Spectrum Disorder DTx Product Overview
- Bipolar Disorder DTx
- Bipolar Disorder DTx Product Overview
- Cardiovascular Disease DTx
- Cardiovascular Disease DTx Product Overview
- Cognitive Assessment DTx
- Cognitive Assessment DTx Product Overview
- Epilepsy DTx
- Epilepsy DTx Product Overview
- Gastrointestinal Disease DTx
- Gastrointestinal Disease DTx Product Overview
- IBS DTx
- IBS DTx Product Overview
- Inflammation DTx
- Inflammation DTx Product Overview
- Major Depressive Disorder DTx
- Major Depressive Disorder DTx Product Overview
- Migraine DTx
- Migraine DTx Product Overview
- Movement Disorders DTx
- Movement Disorders DTx Product Overview
- Oncology DTx
- Oncology DTx Product Overview
- PEAR-006
- PEAR-006 Product Overview
- PEAR-006 Clinical Trial
- PEAR-007
- PEAR-007 Product Overview
- PEAR-010
- PEAR-010 Product Overview
- reCALL
- reCALL Product Overview
- reSET-O+
- reSET-O+ Product Overview
- Respiratory DTx
- Respiratory DTx Product Overview
- reVIVE
- reVIVE Product Overview
- Thrive
- Thrive Product Overview
- Voice Analytics DTx
- Voice Analytics DTx Product Overview
- Pear Therapeutics Inc - Key Competitors
- Pear Therapeutics Inc - Key Employees
- Pear Therapeutics Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Pear Therapeutics Inc, Recent Developments
- Jan 12, 2023: California Department of Health Care Services awards contract to Pear Therapeutics to support the recovery incentives program
- Jan 10, 2023: Pear Therapeutics and COEUS Healthcare partner to combat the addiction crisis with prescription digital therapeutics
- Aug 12, 2022: Pear Therapeutics Reports Second Quarter 2022 Results
- May 02, 2022: Pear Therapeutics to Issue First Quarter 2022 Financial Results on Monday, May 16, 2022
- Feb 17, 2022: Pear Therapeutics to Participate in Citi’s 2022 Virtual Healthcare Conference
- Oct 05, 2021: Pear Therapeutics continues to expand intellectual property portfolio for prescription digital therapeutics
- May 19, 2021: PEAR THERAPEUTICS PRESENTS RESULTS OF TWO ANALYSES SHOWING DECREASES IN HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS IN PATIENTS USING RESET-O® IN TREATING OPIOID USE DISORDER
- Apr 06, 2021: Pear Therapeutics enters into agreements with multiple technology companies
- Feb 10, 2021: Pear Therapeutics to Participate in BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 10, 2021
- Feb 10, 2021: Pear Therapeutics to Participate in BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview
- Pear Therapeutics Inc Pipeline Products by Equipment Type
- Pear Therapeutics Inc Pipeline Products by Indication
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc, Key Facts
- Pear Therapeutics Inc, Major Products and Services
- Pear Therapeutics Inc Number of Pipeline Products by Development Stage
- Pear Therapeutics Inc Pipeline Products Summary by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
- Pear Therapeutics Inc Ongoing Clinical Trials Summary
- Alcohol Use Disorder DTx - Product Status
- Alcohol Use Disorder DTx - Product Description
- Alzheimer’s Disease DTx - Product Status
- Alzheimer’s Disease DTx - Product Description
- Autism Spectrum Disorder DTx - Product Status
- Autism Spectrum Disorder DTx - Product Description
- Bipolar Disorder DTx - Product Status
- Bipolar Disorder DTx - Product Description
- Cardiovascular Disease DTx - Product Status
- Cardiovascular Disease DTx - Product Description
- Cognitive Assessment DTx - Product Status
- Cognitive Assessment DTx - Product Description
- Epilepsy DTx - Product Status
- Epilepsy DTx - Product Description
- Gastrointestinal Disease DTx - Product Status
- Gastrointestinal Disease DTx - Product Description
- IBS DTx - Product Status
- IBS DTx - Product Description
- Inflammation DTx - Product Status
- Inflammation DTx - Product Description
- Major Depressive Disorder DTx - Product Status
- Major Depressive Disorder DTx - Product Description
- Migraine DTx - Product Status
- Migraine DTx - Product Description
- Movement Disorders DTx - Product Status
- Movement Disorders DTx - Product Description
- Oncology DTx - Product Status
- Oncology DTx - Product Description
- PEAR-006 - Product Status
- PEAR-006 - Product Description
- PEAR-006 - Feasibility Study to Treat Depressive Symptoms in People with Multiple Sclerosis
- PEAR-007 - Product Status
- PEAR-007 - Product Description
- PEAR-010 - Product Status
- PEAR-010 - Product Description
- reCALL - Product Status
- reCALL - Product Description
- reSET-O+ - Product Status
- reSET-O+ - Product Description
- Respiratory DTx - Product Status
- Respiratory DTx - Product Description
- reVIVE - Product Status
- reVIVE - Product Description
- Thrive - Product Status
- Thrive - Product Description
- Voice Analytics DTx - Product Status
- Voice Analytics DTx - Product Description
- Pear Therapeutics Inc, Key Employees
- Pear Therapeutics Inc, Other Locations
- Glossary
- Pear Therapeutics Inc Pipeline Products by Equipment Type
- Pear Therapeutics Inc Pipeline Products by Development Stage
- Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Dthera Sciences
- Amylyx Pharmaceuticals Inc
- Puretech Health Plc
- Akili Interactive Labs Inc
- Click Therapeutics Inc
